BPC-157, a stable 15-amino-acid pentadecapeptide derived from a fragment of human gastric juice protein BPC, has been characterised in published research for its effects on angiogenesis, growth-factor signalling and connective-tissue repair across a wide range of injury models
The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea [see Adverse Reactions (6)]
For sustained weight loss, pair interventions: nutrition, behavior change, progressive activity, and, where suitable, medications or supplements backed by trials
Both the LEADER (liraglutide) and SUSTAIN-6 (subcutaneous semaglutide) trials reported significant reductions in the primary outcome (incidence of MACE)
Variability in study design, sample size, and supplement formulations leads to inconsistent results